CHLOROTRIANISENE


Trade Names	CHLOROTRIANISENE TACE
Synonyms	Chlorotrianisene Chlortrianisestrol NSC-10108 Tace Trianisestrol
Status
Molecule Category	UNKNOWN
ATC	G03CA06
UNII	6V5034L121
EPA CompTox	DTXSID1021299


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	BFPSDSIWYFKGBC-UHFFFAOYSA-N
Smiles	COc1ccc(C(Cl)=C(c2ccc(OC)cc2)c2ccc(OC)cc2)cc1
InChI	InChI=1S/C23H21ClO3/c1-25-19-10-4-16(5-11-19)22(17-6-12-20(26-2)13-7-17)23(24)18-8-14-21(27-3)15-9-18/h4-15H,1-3H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C23H21ClO3
Molecular Weight	380.87
AlogP	5.87
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	6.0
Polar Surface Area	27.69
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	27.0

Pharmacology

Mechanism of Action	Action	Reference
Estrogen receptor beta modulator	MODULATOR	PubMed Wikipedia Wikipedia


Protein: Estrogen receptor beta Description: Estrogen receptor beta Organism : Homo sapiens Q92731 ENSG00000140009

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	91

Related Entries

Cross References

Resources	Reference
ChEBI	3641
ChEMBL	CHEMBL1200761
DrugBank	DB00269
DrugCentral	610
FDA SRS	6V5034L121
Human Metabolome Database	HMDB0014414
Guide to Pharmacology	7146
PharmGKB	PA164768822
PubChem	11289
SureChEMBL	SCHEMBL8225
ZINC	ZINC000001530598

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).